{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:49:59Z","timestamp":1793832599925,"version":"4.6.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41577-026-01349-4","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:12:59Z","timestamp":1787155979000},"page":"722-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Living in the age of inflammation: the reverse hygiene hypothesis"],"prefix":"10.1038","volume":"26","author":[{"given":"Luke A. J.","family":"O\u2019Neill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"1349_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/35095542","volume":"1","author":"J Buckland","year":"2001","unstructured":"Buckland, J. The ageing process. Nat. Rev. Immunol. 1, 8 (2001).","journal-title":"Nat. Rev. Immunol."},{"key":"1349_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-75383-0","volume":"17","author":"H Kanemaru","year":"2026","unstructured":"Kanemaru, H. et al. Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy. Nat. Commun. 17, 6534 (2026).","journal-title":"Nat. Commun."},{"key":"1349_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41586-023-06866-z","volume":"626","author":"MP Murphy","year":"2024","unstructured":"Murphy, M. P. & O\u2019Neill, L. A. J. A break in mitochondrial endosymbiosis as a basis for inflammatory diseases. Nature 626, 271\u2013279 (2024).","journal-title":"Nature"},{"key":"1349_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70239","volume":"56","author":"A Cossarizza","year":"2026","unstructured":"Cossarizza, A. Inflammaging: Experimental Insights and Translational Advances. Eur. J. Immunol. 56, e70239 (2026).","journal-title":"Eur. J. Immunol."},{"key":"1349_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10522-026-10477-2","volume":"27","author":"PP Chmielewski","year":"2026","unstructured":"Chmielewski, P. P. Cellular senescence and inflammageing: from mechanisms to senotherapeutic interventions. Biogerontology 27, 129 (2026).","journal-title":"Biogerontology"},{"key":"1349_CR6","doi-asserted-by":"publisher","first-page":"109086","DOI":"10.1016\/j.pharmthera.2026.109086","volume":"16","author":"WH Park","year":"2026","unstructured":"Park, W. H. Mitochondrial dynamics and metabolic regulation in cellular inflammation: From mechanisms to precision therapeutics. Pharmacol. Ther. 16, 109086 (2026).","journal-title":"Pharmacol. Ther."},{"key":"1349_CR7","doi-asserted-by":"publisher","first-page":"1881243","DOI":"10.3389\/fimmu.2026.1881243","volume":"17","author":"Y Huan","year":"2026","unstructured":"Huan, Y. et al. The mitochondrial logic of inflammaging: how energy imbalance drives fibroblast SASP and tissue-specific aging. Front Immunol. 17, 1881243 (2026).","journal-title":"Front Immunol."},{"key":"1349_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.70111","volume":"127","author":"T Malemnganba","year":"2026","unstructured":"Malemnganba, T. et al. Glucose metabolism in immune regulation: from mechanisms to therapeutic opportunities. J. Cell. Biochem. 127, e70111 (2026).","journal-title":"J. Cell. Biochem."},{"key":"1349_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","volume":"46","author":"E Cabral","year":"2025","unstructured":"Cabral, E. et al. Targeting the NLRP3 inflammasome for inflammatory disease therapy. Trends Pharmacol. Sci. 46, 503\u2013519 (2025).","journal-title":"Trends Pharmacol. Sci."},{"key":"1349_CR10","doi-asserted-by":"crossref","unstructured":"Place, D. et al. Selnoflast reduces markers of systemic inflammation in participants with coronary artery disease and elevated C-reactive protein Circulation 152 (Suppl. 3), Abstract 4366197 (2025).","DOI":"10.1161\/circ.152.suppl_3.4366197"},{"key":"1349_CR11","unstructured":"Pagano, G. et al. A phase 1b study to test the safety, pharmacokinetics and pharmacodynamics of selnoflast in early stage Parkinson\u2019s disease. In AD\/PD 2026 Conference https:\/\/medically.roche.com\/global\/en\/neuroscience\/adpd-2026\/medical-material\/ADPD-2026-presentation-pagano-a-phase-1b-study-to-test-the-safety-pharmacokinetics-and-pharmacodynamics-of-selnoflast-pdf.html (2026)."},{"key":"1349_CR12","unstructured":"Laurent, D. et al. Characterisation of DFV890 effect on synovitis activated measured by dynamic-contrast-enhanced (DCE)-MRI in patients with inflammatory knee osteoarthritis. In European Alliance of Associations for Rheumatology Abstract POS0241 (2026)."},{"key":"1349_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12979-023-00395-z","volume":"21","author":"R Liang","year":"2024","unstructured":"Liang, R. et al. The role of NLRP3 inflammasome in aging and age-related diseases. Immun. Ageing 21, 14 (2024).","journal-title":"Immun. Ageing"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01349-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01349-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01349-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:02:21Z","timestamp":1790337741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01349-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01349-4","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"19 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author was a co-founder of Inflazome Ltd, which developed NLRP3 inhibitors that were acquired by Roche Ltd; and of Sitryx Ltd, which is developing therapies that target immunometabolism.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}